Generalised myasthenia gravis - treatment refractory continuing authority application form (PB397)

Use this form to apply to continue PBS-subsidised treatment with ravulizumab for treatment refractory generalised myasthenia gravis.

Page last updated: 1 March 2026.
QC 83705